Xin Lang Cai Jing·2026-02-25 01:27Group 1 - The core viewpoint of the news is that Junshi Biosciences has shown significant trading activity, with a notable financing balance and changes in shareholder structure [1][2]. Group 2 - On February 24, Junshi Biosciences' stock price remained unchanged, with a trading volume of 216 million yuan and a net financing buy of -1.11 million yuan [1]. - As of February 24, the total financing and securities lending balance for Junshi Biosciences reached 1.413 billion yuan, with financing balance accounting for 5.34% of the circulating market value [1]. - The company reported a revenue of 1.806 billion yuan for the first nine months of 2025, representing a year-on-year growth of 42.06%, while the net profit attributable to shareholders was -596 million yuan, an increase of 35.72% year-on-year [2]. - The number of shareholders for Junshi Biosciences increased to 35,900, up by 15.17%, while the average circulating shares per person decreased by 12.96% [2]. - The top ten circulating shareholders include major ETFs, with notable reductions in holdings from E Fund and Huaxia ETFs [2].